Drug Profile
Fentanyl buccal - BioDelivery Sciences/TTY Biopharm
Alternative Names: BEMA-Fentanyl; Breakyl; Fentanyl buccal soluble film; Fentanyl transmucosal - BioDelivery Sciences; Onsolis; PainkylLatest Information Update: 04 Aug 2022
Price :
$50
*
At a glance
- Originator QLT USA
- Developer BioDelivery Sciences International; Meda; TTY Biopharm
- Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Cancer pain
Most Recent Events
- 02 Aug 2022 Adalvo acquired fentanyl buccal soluble film (Onsolis®), taking over all existing business and all market authorizations, globally, including the US
- 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical
- 08 Jul 2019 Launched for Cancer pain in USA, prior July 2019 (Buccal)